Corvus Pharmaceuticals, Inc.
CRVS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.06 | 0.08 | 0.07 | -0.01 |
| FCF Yield | -7.79% | -28.36% | -68.97% | -36.40% |
| EV / EBITDA | -11.57 | -2.73 | -0.71 | -0.96 |
| Quality | ||||
| ROIC | -81.77% | -56.49% | -53.12% | -37.25% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.41 | 0.89 | 0.65 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -6.07% | 12.18% | 25.68% | -5.35% |
| Safety | ||||
| Net Debt / EBITDA | 0.28 | 0.42 | 0.26 | 1.40 |
| Interest Coverage | -15.10 | -14.78 | -49.79 | -2,575.33 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -0.50 | -0.69 |
| Cash Conversion Cycle | -11,087.41 | -3,686.26 | -2,696.23 | -1,771.04 |